The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
August 15th 2025
Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.
Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma
August 14th 2025
s discuss how belantamab mafodotin should be sequenced with chimeric antigen receptor (CAR) T-cell therapy, noting that prior B-cell maturation antigen (BCMA)-directed therapies can reduce CAR T efficacy and recommending CAR T first when patients are candidates.
Panelists discuss how emerging chimeric antigen receptor (CAR) T-cell therapies such as anito-cel show promise with potentially reduced neurologic toxicity while maintaining efficacy, and dual-targeting approaches such as CD19-B-cell maturation antigen (BCMA) constructs may provide better long-term remissions by targeting potential myeloma stem cell populations.
August 12th 2025
Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.
August 10th 2025
The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.
August 9th 2025
The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.
August 7th 2025
Panelists discuss how post-chimeric antigen receptor (CAR) T follow-up care involves coordinated joint visits between academic centers and community oncologists for the first 3 months, with ongoing education about delayed toxicities such as cranial nerve palsies, parkinsonism, and immune effector cell enterocolitis
Panelists discuss how early referral for chimeric antigen receptor (CAR) T-cell therapy is crucial for accessing clinical trials and achieving optimal outcomes, with comprehensive patient education covering unique adverse effects such as cytokine release syndrome (CRS), neurologic toxicities, and secondary malignancies balanced against extraordinary efficacy data.
August 6th 2025
Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.
The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.
Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.
August 5th 2025
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.
Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.
August 1st 2025
Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.
July 31st 2025
Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).
Panelists discuss how the 5-year follow-up data from CARTITUDE-1 shows 33% of patients remain alive and progression-free at 5 years with sustained minimal residual disease (MRD) negativity, suggesting the potential for functional cure in multiple myeloma, with lower disease burden at infusion being a key predictor of long-term remission
Panelists discuss how the CARTITUDE-4 subgroup analysis demonstrated that cilta-cel provides significant progression-free and overall survival advantages over standard of care across all patient subgroups, including those with high-risk cytogenetics, extramedullary disease, and varying numbers of prior therapy lines.
July 30th 2025
Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.
July 27th 2025
The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.